Source: International Congress 2019 – CCC Thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Drösslerová (Opava 5, Czech Republic). A rare choroidal metastasis in ALK+ non-small cell lung cancer (NSCLC) that responds to Crizotinib. International Congress 2019 – CCC Thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015 A rare involvement in a male patient with non-small cell lung carcinoma: breast metastasis Source: Eur Respir J 2005; 26: Suppl. 49, 538s Year: 2005 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients Source: ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017 Year: 2018 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 Prognosis of uncommon metastasis in non-small-cell lung cancer patients with mutated EGFR Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Therapeutic management of ALK+ nonsmall cell lung cancer patients Source: Eur Respir J 2015; 46: 230-242 Year: 2015 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Breast metastasis in association with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 538s Year: 2005 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Management of brain metastases in patients with non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004